TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Tolerability based on Withdrawal Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Actigraphy-Based Sleep Efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Actigraphy-Based Total Sleep Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Safety of the medical device
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptance rate of the SARS-CoV-2 vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes from Baseline Stroke Impact Scale (SIS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes from Baseline Barthel Index (BI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes from Baseline Mini-Mental State Examination (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from Baseline Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TEAE incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pelvic floor impact questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Sotrovimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum-concentration Time Curve From Day 1 to Day 29 (AUC[D1-29]) of Sotrovimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAE) and Common Non-serious Adverse Events (Non-SAE) Through Day 29
Endpoint domain: Adverse events/effects
Primary endpoint: need for postoperative intensive care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: prolongation of postoperative hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Severity of treatment-related adverse events (TRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: 17-item Hamilton Depression Scale (HAMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of traumatic intracranial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of avalanche phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: frequency of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of adverse device effects (ADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of other safety-related signs
Endpoint domain: Adverse events/effects
Primary endpoint: Angiographic evidence of epicardial successful reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angiographic evidence of tissue-level successful reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Falls in the previous 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of falls during the treatment period (8 weeks)
Endpoint domain: Adverse events/effects
Primary endpoint: Engraftment time of neutrophil and platelet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number, frequency and severity of adverse events (AE) within 1 year after infusion of KL003 drug products
Endpoint domain: Adverse events/effects
Primary endpoint: Baseline Adjusted Area Under the Serum Concentration-Time Curve (AUC0-t, adj) of Follitropin Alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline Adjusted Area Under the Serum Concentration-Time Curve (AUC0-t, adj) of Lutropin Alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline Adjusted Maximum Observed Serum Concentration (Cmax,adj) of Follitropin Alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline Adjusted Maximum Observed Serum Concentration (Cmax,adj) of Lutropin Alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak acceleration levels of human impact exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe versus unsafe levels of human impact exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goldmann applanation tonometry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste Evaluation - Aromatic Identity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste Evaluation - Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste Evaluation - Mouthfeel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste Evaluation - Off-notes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste Evaluation - Aftertaste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of high flow nasal canula system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrence of overt hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of procedural Steps Completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Errors in the final skills assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Critical Errors in the final skills assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Errors All Combined (Errors + Critical Errors)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients adherent to bleeding management checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI biomarkers of infarction and penumbra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decreases in Suicidal Ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreases on Self-Injurious Thoughts and Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in responses on the Inventory of Depression and Anxiety Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate or severe CPSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative complications after dexamethasone
Endpoint domain: Adverse events/effects
Primary endpoint: Post operative complications after etoricoxib
Endpoint domain: Adverse events/effects
Primary endpoint: Sentencing severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Barotrauma occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Disease progression or recurrence after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Weight, height and BMI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist hip Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess Weight Loss percentage (EWL%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 68Ga-pentixafor PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of 68Ga-pentixafor PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of 68Ga-pentixafor PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Lu AF90103 and AF88361 in Plasma and Cerebrospinal Fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Lu AF90103 and AF88361 in Plasma and CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful epidural space access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Negative predictive value of the 15-criteria score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective reduction in SCE requests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of C Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of albumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Healing Quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Contrast perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Intervention Uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Intervention Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Health Eating Index (HEI-2015) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postoperative early digestive hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total Number of Antibiotic Treatment Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in blood pressure (systolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood pressure (diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious adverse reactions or adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the pouchitis disease activity index (PDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objectification of nighttime scratching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep in AD-patients
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Set Up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Takedown Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Room Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Shock indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on the Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline on the Dermatology Life Quality Index (DLQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline on the Self-rating Depression Scale (SDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline on the Self-rating Anxiety Scale (SAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of atrial fibrillation episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to complete FOB intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mechanical Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemical Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Upper Quarter Y Balance Test (mUQYBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of candida fungi in vaginal culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Impact of muscular pain on oral health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of muscular pain on anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact of muscular pain on depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Day 28 Ventilator Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Pulmonary Function Testing - Oxygen Diffusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 6 Minute Walk Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: total Pathological Complete Response (tPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Interference Subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Severe Oral Mucositis (WHO grade ≥3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time of maximum plasma observed concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulating EV-derived protein and RNA signatures associated with T2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in circulating EV cargo in patients whose T2D resolves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Inner Arm Visual Skin Crepiness and Laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Upper Arm Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cost of antenatal culture versus intrapartum PCR screening strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of combined symptom and medication score (CSMS) at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total deviation from pre-planned screw entry point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Insertion success ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Role of men's involvement during abortion
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Thyroid nodule volume reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FFR differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NHPR differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure check
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Two hour glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time benefits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Four Weeks (AUC[0-4 Weeks])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration During a Dosing Interval at Steady State (Cmax, ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve During a Dosing Interval at Steady State (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-back Visual correct ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-back visual response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of correct multiple choice responses out of 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of GAD-7 test scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of PHQ-9 test scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Perceived Stress Scale test scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mindful Awareness Attention Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cumulative quantity of morphine received postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: X-ray velocimetry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of mRNA SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence or absence of antibodies anti-SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VascuQol Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Value Changes in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of C1K in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve of C1K from Time Zero to the Last Measurable Point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission Rate to hospital within 90 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of older adults receiving all components of intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time required to respond to a case
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of false positive and false negative errors
Endpoint domain: Adverse events/effects
Primary endpoint: Barhatt performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Breaks from work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients completing at least 80 percent of planned SALSA administrations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity of epilepsy detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: False positives for epilepsy detection
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of force development (N/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability and pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: One year cumulative incidence of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of overall participants recruited and randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of overall participants retained through baseline survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of intervention group participants who agree or completely agree that MyIBD is an acceptable intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in maximal displacement of the medial and lateral gastrocnemius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in delay time of the medial and lateral gastrocnemius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in contraction time of the medial and lateral gastrocnemius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in prefrontal cortex activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximal inter incisal distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in EV-TF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Dual-task Cost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale 17 (HAMD-17) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse events of NS101
Endpoint domain: Adverse events/effects
Primary endpoint: Buccal-lingual/palatal soft tissue dimensional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant stability (ISQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of Obstetric Quality of Recovery-10 Turkish (ObsQoR-10T) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tumor-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: CNOT7 protein expression level in metastatic/advanced localized and non-metastatic BC sera
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNOT7 tissue expression level in BC tissue samples categorized as metastatic vs non-metastatic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes